CYP3A5 and malaria: However, genetic polymorphisms in CQ and PQ metabolizing enzymes that might influence drug availability and response to malaria therapeutic regimen were never investigated; therefore, the present study aims to evaluate whether genetic polymorphisms in G6PD, CYP1A2, CYP2C8, CP2C9, CP3A4 and CYP3A5 influence P. vivax malaria treatment response.